Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Approval Safety Monitoring Program to Assess the Safety Profile of GARDASIL in China Usual Practice

NCT03659110 is registered in ClinicalTrials.gov with Beijing Chaoyang District Centre for Disease Control and Prevention as lead sponsor.

NCT NCT03659110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03659110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Approval Safety Monitoring Program to Assess the Safety Profile of GARDASIL in China Usual Practice
Lead sponsor
Beijing Chaoyang District Centre for Disease Control and Prevention
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2018
Completion date
December 30, 2021
Enrollment
1,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer